Publications

Evaluation of the microbiota-sparing properties of the anti-staphylococcal antibiotic afabicin

Pharmacokinetic-pharmacodynamic modelling of afabicin in vitro activity against Staphylococcus aureus

Antimicrobial activity of the new FabI inhibitor Afabicin desphosphono against intraosteoblastic Staphylococcus aureus

Afabicin, a first-in-class anti-staphylococcal antibiotic, in the treatment of acute bacterial skin and skin structure infections: clinical non-inferiority to vancomycin/linezolid

Staphylococcal-selective antibiotic afabicin preserves the human gut microbiota

The Staphylococcal-specific Antibiotic Debio 1450 Minimizes Disturbance to the Gut Microbiota in Mice

Activity of the novel Fabl inhibitor Debio 1452 against intracellular forms of susceptible and resistant S. aureus: comparison with linezolid,…

Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a FabI Inhibitor, the Prodrug Debio 1450 and…

Safety, tolerability and pharmacokinetics of AFN–1252 administered as immediate release tablets in healthy subjects